


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A compound of the formula:



or pharmaceutically acceptable salts or esters thereof;

wherein X is -(C=O)-, -(C=S)-, or -(C=N-Z), wherein Z [=] is R₂₀ or -OR₂₀;

T is NR₂₀;

wherein each R₂₀ is independently H, -CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ haloalkyl or C₄-C₇ cycloalkyl, with the proviso that when Z is R₂₀ or -OR₂₀, R₂₀ is not -CN;

wherein R₁ is -(CH₂)₁₋₂-S(O)₀₋₂-(C₁-C₆ alkyl), or

C₁-C₁₀ alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, =O, -SH, -C≡N, -CF₃, -C₁-C₃ alkoxy, amino, mono or dialkylamino, -N(R)C(O)R'-, -OC(=O)-amino and -OC(=O)-mono- or dialkylamino, or

C₂-C₆ alkenyl or C₂-C₆ alkynyl, each of which is optionally substituted with 1, 2, or 3 groups independently

selected from halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃
 alkoxy, amino, and mono- or dialkylamino, or
 aryl, heteroaryl, heterocyclyl, -C₁-C₆ alkyl-aryl, -C₁-C₆
 alkyl-heteroaryl, or -C₁-C₆ alkyl-heterocyclyl, where
 the ring portions of each are optionally substituted
 with 1, 2, 3, or 4 groups independently selected from
 halogen, -OH, -SH, -C≡N, -NR₁₀₅R'₁₀₅, -CO₂R, -N(R)COR',
 -N(R)SO₂R', -C(=O)-(C₁-C₄) alkyl, -SO₂-amino, -SO₂-mono
 or dialkylamino, -C(=O)-amino, -C(=O)-mono or
 dialkylamino, -SO₂-(C₁-C₄) alkyl, or
 C₁-C₆ alkoxy optionally substituted with 1, 2, or 3
 halogens, or
 C₃-C₇ cycloalkyl optionally substituted with 1, 2, or 3
 groups independently selected from halogen, -OH,
 -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, amino, -C₁-C₆ alkyl
 and mono- or dialkylamino, or
 C₁-C₁₀ alkyl optionally substituted with 1, 2, or 3
 groups independently selected from halogen, -OH,
 -SH, -C≡N, -CF₃, -C₁-C₃ alkoxy, amino, mono- or
 dialkylamino and -C₁-C₃ alkyl, or
 C₂-C₁₀ alkenyl or C₂-C₁₀ alkynyl each of which is
 optionally substituted with 1, 2, or 3 groups
 independently selected from halogen, -OH, -SH,

-C≡N, -CF₃, C₁-C₃ alkoxy, amino, C₁-C₆ alkyl and mono- or dialkylamino; and the heterocyclyl group is optionally further substituted with oxo;

R and R' independently are hydrogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkylaryl or C₁-C₁₀ alkylheteroaryl;

wherein Rc is

(I) - [-(CH₂)₍₀₋₈₎-(CH)(alkyl₁)(alkyl₂)], where alkyl₁ and alkyl₂ are straight or branched C₂₋₁₀ alkanyl, alkenyl or alkynyl, and wherein alkyl₁ and alkyl₂ attach to the same or different methylene carbon with the remaining open methylene valences occupied by hydrogen, thus forming a branched alkyl chain having between 8 and 20 carbon atoms in total;

the alkyl groups, alkyl₁ and alkyl₂ being optionally substituted with one, two or three substituents selected from the group consisting of C₁-C₃ alkyl, halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, -O-phenyl, -C(O)C₁-C₃ alkyl, -NR_{1-a}R_{1-b} where R_{1-a} and R_{1-b} are -H or C₁-C₆ alkyl, -OC=O NR_{1-a}R_{1-b}, -S(=O)₀₋₂, -NR_{1-a}C=O NR_{1-a}R_{1-b}, -C=O NR_{1-a}R_{1-b}, and -S(=O)₂ NR_{1-a}R_{1-b};

(II) -(C(Rc-x)(Rc-y))₍₀₋₄₎-Rc-cycle

wherein each Rc-x and Rc-y is independently selected from:

H

C₁ - C₆ alkyl

C₁ - C₆ alkoxy

C₂-C₆ alkenyl or alkynyl

-(CH₂)₀₋₄-Rc-cycle where Rc-cycle is as defined below

or Rc-x and Rc-y may be taken together with the methylene carbon to which they jointly attach to form a spirocyclic ring of 3 to 7 atoms comprising carbon and up to 2 of O, S(O)₍₀₋₂₎ and NR_{a'}, wherein R_{a'} is H or C₁₋₄ alkyl;

wherein the spirocyclic ring may be fused to another ring to provide a bicyclic ring system comprising carbon and up to 2 of O, S(O)₍₀₋₂₎ and NR_{a'}. and comprising up to 9 atoms in total including,

Rc-cycle is aryl, heteroaryl, cycloalkyl or a fused-ring system consisting of no more than three rings where each of the rings is the same or different and is an aryl, heteroaryl, or cycloalkyl ring

wherein Rc-cycle is optionally substituted with up to four substituents independently selected from:

(1) C₁-C₆ alkyl optionally substituted with one, two or three substituents selected from the group consisting of C₁-C₃ alkyl, halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR_{1-a}R_{1-b},

(2) C₂-C₆ alkenyl or alkynyl with one or two unsaturated bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR_{1-a}R_{1-b},

(3) halogen,

- (4) C₁-C₆ alkoxy,
- (5) -C₁-C₆ alkoxy optionally substituted with one, two, or three of -F,
- (6) -NR_{N-6}R_{N-7} where R_{N-6} and R_{N-7} are the same or different and are selected from the group consisting of:
- (a) -H,
- (b) -C₁-C₆ alkyl optionally substituted with one substituent selected from the group consisting of:
- (i) -OH, and
- (ii) -NH₂,
- (c) -C₁-C₆ alkyl optionally substituted with one to three -F, -Cl, -Br, or -I,
- (d) -C₃-C₇ cycloalkyl,
- (e) -(C₁-C₂ alkyl)-(C₃-C₇ cycloalkyl),
- (f) -(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl),
- (g) -C₂-C₆ alkenyl with one or two double bonds,
- (h) -C₂-C₆ alkynyl with one or two triple bonds,
- (i) -C₁-C₆ alkyl chain with one double bond and one triple bond,
- (j) aryl, and
- (k) heteroaryl,
- (7) -OH,
- (8) -C≡N,

(9) C₃-C₇ cycloalkyl, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR_{1-a}R_{1-b},

(10) -CO-(C₁-C₄ alkyl),

(11) -SO₂-NR_{1-a}R_{1-b},

(12) -CO-NR_{1-a}R_{1-b},

(13) -SO₂-(C₁-C₄ alkyl),

and when there is a saturated carbon atom in R_C-cycle

(14) oxo,

(15) oxime

(16) ketal rings of 5 to 7 members, and

(17) a spirocyclic ring having from 3 to 7 atoms comprising carbon and when the ring size is 4-7 atoms optionally up to 2 of O, S(O)₍₀₋₂₎ and NR_a,

(III) - (CR_{C-x}R_{C-y})₀₋₄-aryl-aryl ,

(IV) - (CR_{C-x}R_{C-y})₀₋₄-aryl-heteroaryl,

(V) - (CR_{C-x}R_{C-y})₀₋₄- heteroaryl-aryl,

(VI) - (CR_{C-x}R_{C-y})₀₋₄- heteroaryl-heteroaryl,

(VII) - (CR_{C-x}R_{C-y})₀₋₄- aryl-heterocycle,

(VIII) - (CR_{C-x}R_{C-y})₀₋₄-heteroaryl-heterocycle,

(IX) - (CR_{C-x}R_{C-y})₀₋₄-heterocycle-aryl,

(X) - (CR_{C-x}R_{C-y})₀₋₄-heterocycle-heteroaryl,

(XI) - (CR_{C-x}R_{C-y})₀₋₄- heterocycle-heterocycle,

(XII) $-[C(R_{C-1})(R_{C-2})]_{1-3}-[CO]_{0-1}-N-(R_{C-3})_2$ where each R_{C-1} is the same or different and is selected from the group consisting of H, C_{1-4} alkyl and C_{1-4} alkoxy, where each R_{C-2} and R_{C-3} is independently selected from

(A) $-C_1-C_6$ alkyl optionally substituted with one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-SH$, $-C\equiv N$, $-CF_3$, C_1-C_6 alkoxy, $-O$ -phenyl, and $-NR_{1-a}R_{1-b}$,

(B) C_2-C_6 alkenyl or alkynyl with one or two unsaturated bonds, optionally substituted with one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-SH$, $-C\equiv N$, $-CF_3$, C_1-C_6 alkoxy, $-O$ -phenyl, and $-NR_{1-a}R_{1-b}$,

(C) $-(CH_2)_{1-2}-S(O)_{0-2}-(C_1-C_6 \text{ alkyl})$,

(D) $-(CH_2)_{0-4}-C_3-C_7$ cycloalkyl optionally substituted with one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-SH$, $-C\equiv N$, $-CF_3$, C_1-C_6 alkoxy, $-O$ -phenyl, and $-NR_{1-a}R_{1-b}$,

(E) $-(CH_2)_{0-4}-5-7$ membered heterocycle optionally substituted with one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, $-F$, $-Cl$, $-Br$, $-I$, $-OH$, $-SH$, $-C\equiv N$, $-CF_3$, C_1-C_6 alkoxy, $-O$ -phenyl, oxo, and $-NR_{1-a}R_{1-b}$,

(XIII) $-CH(aryl)_2$ where each aryl is the same or different,

(XIV) $-\text{CH}(\text{heteroaryl})_2$ where each heteroaryl is the same or different and are as defined above,

(XVIII) $-\text{CH}(\text{aryl})(\text{heteroaryl})$;

wherein R_N is R'_{100} , $-(\text{CRR}')_{1-6}R'_{100}$, $-(\text{CRR}')_{0-6}R_{100}$, $-(\text{CRR}')_{1-6}-O-$

R'_{100} , $-(\text{CRR}')_{1-6}-S-R'_{100}$, $-(\text{CRR}')_{1-6}-C(=O)-R_{100}$, $-(\text{CRR}')_{1-6}-SO_2-$

R_{100} , $-(\text{CRR}')_{1-6}-NR_{100}-R'_{100}$ or $-SO_2R'_{100}$, with the proviso that

when R_N is $-SO_2R'_{100}$, X is not $-S(=O)_n-$ or $-C(=S)-$; wherein

R_{100} and R'_{100} are independently aryl, heteroaryl, $-\text{aryl}-W\text{-aryl}$, $-\text{aryl}-W\text{-heteroaryl}$,

$-\text{aryl}-W\text{-heterocyclyl}$, $-\text{heteroaryl}-W\text{-aryl}$, $-\text{heteroaryl}-W\text{-heteroaryl}$,

$-\text{heteroaryl}-W\text{-heterocyclyl}$, $-\text{heterocyclyl}-W\text{-aryl}$, $-\text{heterocyclyl}-W\text{-heteroaryl}$,

$-\text{heterocyclyl}-W\text{-heterocyclyl}$, $-\text{CH}[(\text{CH}_2)_{0-2}-O-$

$R_{150}]-(\text{CH}_2)_{0-2}\text{-aryl}$, $-\text{CH}[(\text{CH}_2)_{0-2}-O-R_{150}]-(\text{CH}_2)_{0-2}\text{-heterocyclyl}$

or $-\text{CH}[(\text{CH}_2)_{0-2}-O-R_{150}]-(\text{CH}_2)_{0-2}\text{-heteroaryl}$, where the ring

portions of each are optionally substituted with 1, 2, or 3

groups independently selected from

$-\text{OR}$, $-\text{NO}_2$, halogen, $-\text{C}\equiv\text{N}$, $-\text{OCF}_3$, $-\text{CF}_3$, $-(\text{CH}_2)_{0-4}-O-$

$\text{P}(=\text{O})(\text{OR})(\text{OR}')$, $-(\text{CH}_2)_{0-4}-\text{CO}-\text{NR}_{105}R'_{105}$, $-(\text{CH}_2)_{0-4}-O-(\text{CH}_2)_{0-4}-\text{CONR}_{102}R_{102}'$,

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_1\text{-C}_{12}\text{ alkyl})$, $-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_2\text{-C}_{12}\text{ alkenyl})$,

$-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_2\text{-C}_{12}\text{ alkynyl})$, $-(\text{CH}_2)_{0-4}-\text{CO}-(\text{C}_3\text{-C}_7\text{ cycloalkyl})$,

$-(\text{CH}_2)_{0-4}-R_{110}$, $-(\text{CH}_2)_{0-4}-R_{120}$, $-(\text{CH}_2)_{0-4}-R_{130}$,

$-(\text{CH}_2)_{0-4}-\text{CO}-R_{110}$, $-(\text{CH}_2)_{0-4}-\text{CO}-R_{120}$, $-(\text{CH}_2)_{0-4}-\text{CO}-R_{130}$,

$-(\text{CH}_2)_{0-4}-\text{CO}-R_{140}$, $-(\text{CH}_2)_{0-4}-\text{CO}-O-R_{150}$,

$-(\text{CH}_2)_{0-4}-\text{CO}-R_{150}$, $-(\text{CH}_2)_{0-4}-\text{CO}-R_{160}$, $-(\text{CH}_2)_{0-4}-\text{CO}-O-R_{170}$,

$-(\text{CH}_2)_{0-4}-\text{SO}_2-\text{NR}_{105}\text{R}'_{105}$, $-(\text{CH}_2)_{0-4}-\text{SO}-(\text{C}_1-\text{C}_8 \text{ alkyl})$,
 $-(\text{CH}_2)_{0-4}-\text{SO}_2-(\text{C}_1-\text{C}_{12} \text{ alkyl})$, $-(\text{CH}_2)_{0-4}-\text{SO}_2-(\text{CH}_2)_{0-4}-(\text{C}_3-\text{C}_7$
 $\text{cycloalkyl})$, $-(\text{CH}_2)_{0-4}-\text{N}(\text{R}_{150})-\text{CO}-\text{O}-\text{R}_{150}$, $-(\text{CH}_2)_{0-4}-\text{N}(\text{R}_{150})-$
 $\text{CO}-\text{N}(\text{R}_{150})_2$, $-(\text{CH}_2)_{0-4}-\text{N}(\text{R}_{150})-\text{CS}-\text{N}(\text{R}_{150})_2$, $-(\text{CH}_2)_{0-4}-\text{N}(\text{R}_{150})-$
 $\text{CO}-\text{R}_{105}$, $-(\text{CH}_2)_{0-4}-\text{NR}_{105}\text{R}'_{105}$, $-(\text{CH}_2)_{0-4}-\text{R}_{140}$, $-(\text{CH}_2)_{0-4}-\text{O}-\text{CO}-$
 $(\text{C}_1-\text{C}_6 \text{ alkyl})$, $-(\text{CH}_2)_{0-4}-\text{O}-\text{P}(\text{O})-(\text{O}-\text{R}_{110})_2$, $-(\text{CH}_2)_{0-4}-\text{O}-\text{CO}-$
 $\text{N}(\text{R}_{150})_2$, $-(\text{CH}_2)_{0-4}-\text{O}-\text{CS}-\text{N}(\text{R}_{150})_2$, $-(\text{CH}_2)_{0-4}-\text{O}-(\text{R}_{150})$,
 $-(\text{CH}_2)_{0-4}-\text{O}-\text{R}_{150}'-\text{COOH}$, $-(\text{CH}_2)_{0-4}-\text{S}-(\text{R}_{150})$, $-(\text{CH}_2)_{0-4}-$
 $\text{N}(\text{R}_{150})-\text{SO}_2-\text{R}_{105}$, $-(\text{CH}_2)_{0-4}-\text{C}_3-\text{C}_7 \text{ cycloalkyl}$, $(\text{C}_2-$
 $\text{C}_{10})\text{alkenyl}$, and $(\text{C}_2-\text{C}_{10})\text{alkynyl}$, or

R_{100} is C_1-C_{10} alkyl optionally substituted with 1, 2, or 3 R_{115}
 groups, or

R_{100} is $-(\text{C}_1-\text{C}_6 \text{ alkyl})-\text{O}-\text{C}_1-\text{C}_6 \text{ alkyl}$ or $-(\text{C}_1-\text{C}_6 \text{ alkyl})-\text{S}-(\text{C}_1-\text{C}_6$
 $\text{alkyl})$, each C_1-C_6 alkyl is optionally substituted with 1,
 2, or 3 R_{115} groups, or

R_{100} is C_3-C_8 cycloalkyl optionally substituted with 1, 2, or 3
 R_{115} groups;

W is a bond, $-(\text{CH}_2)_{1-4}-$, $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{N}(\text{R}_{135})-$, $-\text{CR}(\text{OH})-$ or $-$
 $\text{C}(\text{O})-$;

R_{102} and R_{102}' independently are hydrogen, or

C_1-C_{10} alkyl optionally substituted with 1, 2, or 3 groups
 that are independently halogen, aryl or $-\text{R}_{110}$;

R₁₀₅ and R'₁₀₅ independently are -H, -R₁₁₀, -R₁₂₀, C₃-C₇ cycloalkyl, -(C₁-C₂ alkyl)-(C₃-C₇ cycloalkyl), -(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl), C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl chain with one double bond and one triple bond, C₁-C₆ alkyl optionally substituted with -OH or -NH₂, or C₁-C₆ alkyl optionally substituted with 1, 2, or 3 halogens, or

R₁₀₅ and R'₁₀₅ together with the atom to which they are attached form a 3 to 7 membered carbocyclic ring, where one member is optionally a heteratom selected from -O-, -S(O)₀₋₂-, -N(R₁₃₅)-, the ring being optionally substituted with 1, 2 or three R₁₄₀ groups;

R₁₁₅ at each occurrence is independently halogen, -OH, -CO₂R₁₀₂, -C₁-C₆ thioalkoxy, -CO₂-phenyl, -NR₁₀₅R'₁₃₅, -SO₂-(C₁-C₈ alkyl), -C(=O)R₁₈₀, R₁₈₀, -CONR₁₀₅R'₁₀₅, -SO₂NR₁₀₅R'₁₀₅, -NH-CO-(C₁-C₆ alkyl), -NH-C(=O)-OH, -NH-C(=O)-OR, -NH-C(=O)-O-phenyl, -O-C(=O)-(C₁-C₆ alkyl), -O-C(=O)-amino, -O-C(=O)-mono- or dialkylamino, -O-C(=O)-phenyl, -O-(C₁-C₆ alkyl)-CO₂H, -NH-SO₂-(C₁-C₆ alkyl), C₁-C₆ alkoxy or C₁-C₆ haloalkoxy;

R₁₃₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, -(CH₂)₀₋₂-(aryl), -(CH₂)₀₋₂-(heteroaryl), or -(CH₂)₀₋₂-(heterocyclyl);

R₁₄₀ is heterocyclcyl optionally substituted with 1, 2, 3, or 4 groups independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, and =O;

R₁₅₀ is hydrogen, C₃-C₇ cycloalkyl, -(C₁-C₂ alkyl)-(C₃-C₇ cycloalkyl), C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl with one double bond and one triple bond, -R₁₁₀, -R₁₂₀, or C₁-C₆ alkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from -OH, -NH₂, C₁-C₃ alkoxy, R₁₁₀, and halogen;

R_{150'} is C₃-C₇ cycloalkyl, -(C₁-C₃ alkyl)-(C₃-C₇ cycloalkyl), C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkyl with one double bond and one triple bond, -R₁₁₀, -R₁₂₀, or C₁-C₆ alkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from -OH, -NH₂, C₁-C₃ alkoxy, R₁₁₀, and halogen;

R₁₈₀ is selected from morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S-oxide, homothiomorpholinyl S,S-dioxide, pyrrolinyl and pyrrolidinyl, each of which is

optionally substituted with 1, 2, 3, or 4 groups independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, and =O;

R₁₁₀ is aryl optionally substituted with 1 or 2 R₁₂₅ groups;

R₁₂₅ at each occurrence is independently halogen, amino, mono- or dialkylamino, -OH, -C≡N, -SO₂-NH₂, -SO₂-NH-C₁-C₆ alkyl, -SO₂-N(C₁-C₆ alkyl)₂, -SO₂-(C₁-C₄ alkyl), -CO-NH₂, -CO-NH-C₁-C₆ alkyl, or -CO-N(C₁-C₆ alkyl)₂, or

C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein each C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl is optionally substituted with 1, 2, or 3 groups that are independently selected from C₁-C₃ alkyl, halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, amino, and mono- and dialkylamino, or

C₁-C₆ alkoxy optionally substituted with one, two or three halogens;

R₁₂₀ is heteroaryl optionally substituted with 1 or 2 R₁₂₅ groups; and

R₁₃₀ is heterocyclyl optionally substituted with 1 or 2 R₁₂₅ groups;

R₂ is selected from the group consisting of H; C₁-C₆ alkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₃ alkyl, halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR_{1-a}R_{1-b}; wherein R_{1-a} and R_{1-b} are -H or C₁-C₆ alkyl; -(CH₂)₀₋₄-aryl; -(CH₂)₀₋₄-heteroaryl; C₂-C₆ alkenyl; C₂-C₆ alkynyl; -CONR_{N-2}R_{N-3}; -SO₂NR_{N-2}R_{N-3}; -CO₂H; and -CO₂-(C₁-C₄ alkyl);

R₃ is selected from the group consisting of H; C₁-C₆ alkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₃ alkyl, halogen, -OH, -SH, -C≡N, -CF₃, C₁-C₃ alkoxy, and -NR_{1-a}R_{1-b}; -(CH₂)₀₋₄-aryl; -(CH₂)₀₋₄-heteroaryl; C₂-C₆ alkenyl; C₂-C₆ alkynyl; -CO-NR_{N-2}R_{N-3}; -SO₂-NR_{N-2}R_{N-3}; -CO₂H; and -CO-O-(C₁-C₄ alkyl);

wherein

R_{N-2} and R_{N-3} at each occurrence are independently selected from the group consisting of -C₁-C₈ alkyl optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of -OH, -NH₂, phenyl and halogen; -C₃-C₈ cycloalkyl; -(C₁-C₂ alkyl)-(C₃-C₈ cycloalkyl); -(C₁-C₆ alkyl)-O-(C₁-C₃


alkyl); -C₂-C₆ alkenyl; -C₂-C₆ alkynyl; -C₁-C₆ alkyl chain with one double bond and one triple bond; aryl; heteroaryl; and heterocycloalkyl; or

R_{N-2}, R_{N-3} and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or heteroaryl group, wherein said heterocycloalkyl or heteroaryl group is optionally fused to a benzene, pyridine, or pyrimidine ring, and said groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that at each occurrence are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, halo C₁-C₆ alkyl, halo C₁-C₆ alkoxy, -CN, -NO₂, -NH₂, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), -OH, -C(O)NH₂, -C(O)NH(C₁-C₆ alkyl), -C(O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl), C₁-C₆ alkoxy C₁-C₆ alkyl, C₁-C₆ thioalkoxy, and C₁-C₆ thioalkoxy C₁-C₆ alkyl; or

R₂, R₃ and the carbon to which they are attached form a carbocycle of three thru seven carbon atoms, wherein one carbon atom is optionally replaced by a group selected from -O-, -S-, -SO₂-, or -NR_{N-2}-.

2. (Canceled)

3. (Original) A compound according to claim 1 of the formula



or a pharmaceutically acceptable salt or ester thereof wherein

R_C is selected from -(CH₂)₀₋₃-(C₃-C₈) cycloalkyl wherein the

cycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from -R₂₀₅; and -CO₂-(C₁-C₄ alkyl);

-(CR₂₄₅R₂₅₀)₀₋₄-aryl; -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl; -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl; -(CR₂₄₅R₂₅₀)₀₋₄-aryl-heteroaryl; -(CR₂₄₅R₂₅₀)₀₋₄-aryl-heterocycloalkyl; -(CR₂₄₅R₂₅₀)₀₋₄-aryl-aryl; -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-aryl; -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heterocycloalkyl; -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heteroaryl; -CHR₂₄₅-CHR₂₅₀-aryl; -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heteroaryl; -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heterocycloalkyl; -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-aryl; a monocyclic or bicyclic ring of 5, 6, 7 8, 9, or 10 carbons fused to 1 or 2 aryl, heteroaryl, or heterocycloalkyl groups;

wherein 1, 2 or 3 carbons of the monocyclic or bicyclic ring are optionally replaced with -NH-, -N(CO)₀₋₁R₂₁₅-, -N(CO)₀₋₁R₂₂₀-, -O-, or -S(=O)₀₋₂-, and wherein the monocyclic or bicyclic ring is optionally substituted with 1, 2 or 3 groups that are independently -R₂₀₅, -R₂₄₅, -R₂₅₀ or =O; and -C₂-C₆ alkenyl optionally substituted with 1, 2, or 3

R₂₀₅ groups;

wherein each aryl or heteroaryl group attached directly or indirectly to the $-(CR_{245}R_{250})_{0-4}$ group is optionally substituted with 1, 2, 3 or 4 R_{200} groups;

wherein each heterocycloalkyl attached directly or indirectly to the $-(CR_{245}R_{250})_{0-4}$ group is optionally substituted with 1, 2, 3, or 4 R_{210} ;

R_{200} at each occurrence is independently selected from

$-C_1-C_6$ alkyl optionally substituted with 1, 2, or 3 R_{205} groups; $-OH$; $-NO_2$; $-halogen$; $-C\equiv N$; $-(CH_2)_{0-4}-CO-NR_{220}R_{225}$; $-(CH_2)_{0-4}-CO-(C_1-C_8 \text{ alkyl})$; $-(CH_2)_{0-4}-CO-(C_2-C_8 \text{ alkenyl})$; $-(CH_2)_{0-4}-CO-(C_2-C_8 \text{ alkynyl})$; $-(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl})$; $-(CH_2)_{0-4}-(CO)_{0-1}-aryl$; $-(CH_2)_{0-4}-(CO)_{0-1}-heteroaryl$; $-(CH_2)_{0-4}-(CO)_{0-1}-heterocycloalkyl$; $-(CH_2)_{0-4}-CO_2R_{215}$; $-(CH_2)_{0-4}-SO_2-NR_{220}R_{225}$; $-(CH_2)_{0-4}-S(O)_{0-2}-(C_1-C_8 \text{ alkyl})$; $-(CH_2)_{0-4}-S(O)_{0-2}-(C_3-C_7 \text{ cycloalkyl})$; $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO_2R_{215}$; $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-SO_2-R_{220}$; $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO-N(R_{215})_2$; $-(CH_2)_{0-4}-N(-H \text{ or } R_{215})-CO-R_{220}$; $-(CH_2)_{0-4}-NR_{220}R_{225}$; $-(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl})$; $-(CH_2)_{0-4}-O-(R_{215})$; $-(CH_2)_{0-4}-S-(R_{215})$; $-(CH_2)_{0-4}-O-(C_1-C_6 \text{ alkyl optionally substituted with 1, 2, 3, or 5 -F})$; $-C_2-C_6 \text{ alkenyl optionally substituted with 1 or 2 } R_{205} \text{ groups}$; $-C_2-C_6 \text{ alkynyl optionally}$

substituted with 1 or 2 R₂₀₅ groups; adamantly, and
-(CH₂)₀₋₄- C₃-C₇ cycloalkyl;

each aryl and heteroaryl group included within R₂₀₀
is optionally substituted with 1, 2, or 3
groups that are independently -R₂₀₅, -R₂₁₀ or -
C₁-C₆ alkyl substituted with 1, 2, or 3 groups
that are independently R₂₀₅ or R₂₁₀;

each heterocycloalkyl group included within R₂₀₀ is
optionally substituted with 1, 2, or 3 groups
that are independently R₂₁₀;

R₂₀₅ at each occurrence is independently selected from
-C₁-C₆ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -C₁-C₆
haloalkoxy, -(CH₂)₀₋₃(C₃-C₇ cycloalkyl), -halogen,
-(CH₂)₀₋₆-OH, -O-phenyl, OH, SH, -(CH₂)₀₋₆-C≡N,
-(CH₂)₀₋₆-C(=O)NR₂₃₅R₂₄₀, -CF₃, -C₁-C₆ alkoxy, C₁-C₆
alkoxycarbonyl, and -NR₂₃₅R₂₄₀;

R₂₁₀ at each occurrence is independently selected from
-C₁-C₆ alkyl optionally substituted with 1, 2, or
3 R₂₀₅ groups; -C₂-C₆ alkenyl optionally
substituted with 1, 2, or 3 R₂₀₅ groups; C₁-C₆
alkanoyl; -SO₂-(C₁-C₆ alkyl); -C₂-C₆ alkynyl
optionally substituted with 1, 2, or 3 R₂₀₅ groups;
-halogen; -C₁-C₆ alkoxy; -C₁-C₆ haloalkoxy;
-NR₂₂₀R₂₂₅; -OH; -C≡N; -C₃-C₇ cycloalkyl optionally

substituted with 1, 2, or 3 R₂₀₅ groups; -CO-(C₁-C₄ alkyl); -SO₂-NR₂₃₅R₂₄₀; -CO-NR₂₃₅R₂₄₀; -SO₂-(C₁-C₄ alkyl); and =O;

R₂₁₅ at each occurrence is independently selected from -C₁-C₆ alkyl, -(CH₂)₀₋₂-(aryl), -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -C₃-C₇ cycloalkyl, -(CH₂)₀₋₂-(heteroaryl), and -(CH₂)₀₋₂-(heterocycloalkyl); wherein the aryl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 groups that are independently -R₂₀₅ or -R₂₁₀; wherein the heterocycloalkyl and heteroaryl groups included within R₂₁₅ are optionally substituted with 1, 2, or 3 R₂₁₀;

R₂₂₀ at each occurrence is independently H, -C₁-C₆ alkyl, -CHO, hydroxy C₁-C₆ alkyl, C₁-C₆ alkoxycarbonyl, -amino C₁-C₆ alkyl, -SO₂-C₁-C₆ alkyl, C₁-C₆ alkanoyl optionally substituted with up to three halogens, -C(O)NH₂, -C(O)NH(C₁-C₆ alkyl), -C(O)N(C₁-C₆ alkyl)(C₁-C₆ alkyl), -halo C₁-C₆ alkyl, -(CH₂)₀₋₂-(C₃-C₇ cycloalkyl), -(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl), -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -aryl, -heteroaryl, or -heterocycloalkyl; wherein the aryl, heteroaryl and heterocycloalkyl groups included within R₂₂₀

and R₂₂₅ is optionally substituted with 1, 2, or 3 R₂₇₀ groups,

R₂₇₀ at each occurrence is independently -R₂₀₅, -C₁-C₆ alkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups; -C₂-C₆ alkenyl optionally substituted with 1, 2, or 3 R₂₀₅ groups; -C₂-C₆ alkynyl optionally substituted with 1, 2, or 3 R₂₀₅ groups; -phenyl; -halogen; -C₁-C₆ alkoxy; -C₁-C₆ haloalkoxy; -NR₂₃₅R₂₄₀; -OH; -C≡N; -C₃-C₇ cycloalkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups; -CO-(C₁-C₄ alkyl); -SO₂-NR₂₃₅R₂₄₀; -CO-NR₂₃₅R₂₄₀; -SO₂-(C₁-C₄ alkyl); and =O;

R₂₃₅ and R₂₄₀ at each occurrence are independently -H, -C₁-C₆ alkyl, C₂-C₆ alkanoyl, -SO₂-(C₁-C₆ alkyl), or -phenyl;

R₂₄₅ and R₂₅₀ at each occurrence are independently selected from H, -(CH₂)₀₋₄CO₂C₁-C₄ alkyl, -(CH₂)₀₋₄C(=O)C₁-C₄ alkyl, -C₁-C₄ alkyl, -C₁-C₄ hydroxyalkyl, -C₁-C₄ alkoxy, -C₁-C₄ haloalkoxy, -(CH₂)₀₋₄-C₃-C₇ cycloalkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -(CH₂)₀₋₄ aryl, -(CH₂)₀₋₄ heteroaryl, and -(CH₂)₀₋₄ heterocycloalkyl, or R₂₄₅ and R₂₅₀ are taken together with the carbon to which they are attached to form a monocycle or bicycle of 3, 4, 5, 6, 7 or 8 carbon atoms, where 1, 2, or 3 carbon atoms are optionally

replaced by 1, 2, or 3 groups that are independently -O-, -S-, -SO₂-, -C(O)-, -NR₂₂₀-, or -NR₂₂₀R₂₂₀- wherein both R₂₂₀ groups are alkyl; and wherein the ring is optionally substituted with 1, 2, 3, 4, 5, or 6 groups that are independently C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxyl, NH₂, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), -NH-C(O)C₁-C₅ alkyl, -NH-SO₂-(C₁-C₆ alkyl), or halogen;

wherein the aryl, heteroaryl or heterocycloalkyl groups

included within R₂₄₅ and R₂₅₀ are optionally substituted with 1, 2, or 3 groups that are independently halogen, C₁₋₆ alkyl, CN or OH.

4. (Original) A compound according to claim 3, wherein R₁ is C₁-C₁₀ alkyl optionally substituted with 1 or 2 groups independently selected from halogen, -OH, =O, -CN, -CF₃, -OCF₃, -C₃-C₇ cycloalkyl, -C₁-C₄ alkoxy, amino, mono-dialkylamino, aryl, heteroaryl or heterocycloalkyl, wherein the aryl group is optionally substituted with 1 or 2 R₅₀ groups;

R₅₀ is halogen, OH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, and C₃-C₈ cycloalkyl;

R₇ and R₈ are selected from H; -C₁-C₄ alkyl optionally substituted with 1, 2, or 3 groups selected from

-OH, -NH₂ and halogen; -C₃-C₆ cycloalkyl; -(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl); -C₂-C₄ alkenyl; and -C₂-C₄ alkynyl;

R_C is selected from -(CR₂₄₅R₂₅₀)₀₋₄-aryl; -(CR₂₄₅R₂₅₀)₀₋₄-heteroaryl; -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl; where the aryl and heteroaryl groups attached to the -(CR₂₄₅R₂₅₀)₀₋₄- group are optionally substituted with 1, 2, 3 or 4 R₂₀₀ groups; where the heterocycloalkyl group attached to the -(CR₂₄₅R₂₅₀)₀₋₄ group is optionally substituted with 1, 2, 3, or 4 R₂₁₀ groups; and R₂₄₅, R₂₅₀, R₂₀₀, and R₂₁₀ are as defined above.

5. (Original) A compound according to claim 4, wherein R_C is -(CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl; where the heterocycloalkyl group attached to the -(CR₂₄₅R₂₅₀)₀₋₄- group is optionally substituted with 1, 2, 3, or 4 R₂₁₀ groups, wherein R₂₄₅, R₂₅₀, and R₂₁₀ are as defined above.

6 (Original) A compound according to claim 5, wherein R₁ is C₁-C₁₀ alkyl substituted with one aryl group, where the aryl group is optionally substituted with 1 or 2 R₅₀ groups; R_C is -(CR₂₄₅R₂₅₀)₁₋₄-aryl or -(CR₂₄₅R₂₅₀)₁₋₄-heteroaryl,

R₂₄₅ and R₂₅₀ are independently selected from H, -(CH₂)₀₋₄CO₂C₁-C₄ alkyl, -(CH₂)₀₋₄CO₂H, -C₁-C₄ alkyl, -(C₁-C₄ alkyl)OH, or

R₂₄₅, R₂₅₀ and the carbon to which they are attached form a monocycle or bicycle of 3, 4, 5, 6, 7 or 8 carbon atoms, where 1 or 2 carbon atoms are optionally replaced by -O-, -S-, -SO₂-, or -NR₂₂₀-, where R₂₂₀ is as defined above; and

wherein the aryl and heteroaryl groups attached to the

(CR₂₄₅R₂₅₀)₁₋₄- groups are optionally substituted with 1 or 2 R₂₀₀ groups.

7. (Original) A compound according to claim 3, wherein R_C is (CR₂₄₅R₂₅₀)₁-aryl, where the aryl (preferably phenyl or naphthyl, more preferably phenyl) is optionally substituted with 1, 2, or 3 R₂₀₀ groups; and R₂₄₅ is H and R₂₅₀ is H or C₁-C₆ alkyl; or R₂₄₅ and R₂₅₀ are independently C₁-C₃ alkyl (preferably both are methyl); or CR₂₄₅R₂₅₀ represents a C₃-C₇ cycloalkyl group.

8. (Original) A compound according to claim 7, wherein the (CR₂₄₅R₂₅₀)₁-aryl is (CR₂₄₅R₂₅₀)₁-phenyl where the phenyl is optionally substituted with 1, 2, or 3 R₂₀₀ groups.

9. (Original) A compound according to claim 8, wherein the phenyl in (CR₂₄₅R₂₅₀)₁-phenyl is substituted with 1-3 independently selected R₂₀₀ groups, or

1 or 2 independently selected R_{200} groups, and
1 heteroaryl group optionally substituted with 1 R_{200} group or 1
phenyl group optionally substituted with 1 R_{200} group.

10. (Original) A compound according to claim 8, wherein R_{245}
is hydrogen and R_{250} is C_1 - C_3 alkyl.

11. (Original) A compound according to claim 8, wherein R_{245}
and R_{250} are both hydrogen.

12. (Previously presented) A compound according to claim 8,
wherein the phenyl in $(CR_{245}R_{250})_1$ -phenyl is substituted with

(a) 1 R_{200} group and 1 heteroaryl group, wherein the
heteroaryl is optionally substituted with 1 R_{200} group; or

(b) 1 R_{200} group and 1 phenyl group, wherein the 1 phenyl
group is optionally substituted with 1 R_{200} group; or

(c) 1 R_{200} group and 1 heterocycloalkyl group wherein the
heterocycloalkyl group is optionally substituted with 1 R_{200}
group or =O.

13. (Original) A compound according to claim 12, wherein
 $CR_{245}R_{250}$ represents a C_3 - C_7 cycloalkyl group.

14. (Original) A compound according to claim 12, wherein $\text{CR}_{245}\text{R}_{250}$ represents a $\text{C}_5\text{-C}_7$ cycloalkyl group.

15. (Original) A compound according to claim 12, wherein $\text{CR}_{245}\text{R}_{250}$ represents a $\text{C}_3\text{-C}_6$ cycloalkyl group.

16. (Original) A compound according to claim 12, wherein $\text{CR}_{245}\text{R}_{250}$ represents a C_6 cycloalkyl.

17. (Previously presented) A compound according to claim 8, wherein the phenyl in $(\text{CR}_{245}\text{R}_{250})_1\text{-phenyl}$ is substituted with

1 R_{200} group; or

1 R_{200} group and one heteroaryl group wherein the heteroaryl group is optionally substituted with

1 R_{200} group or

1 R_{200} group and 1 phenyl group wherein the 1

phenyl group is optionally substituted with one R_{200} group.

18. (Original) A compound according to claim 8, wherein the phenyl in $(\text{CR}_{245}\text{R}_{250})_1\text{-phenyl}$ is substituted with 1 R_{200} group.

19. (Previously presented) A compound selected from the group consisting of:

methyl (3*S*)-3-{ [(2*R*,3*S*)-3-[(anilinocarbonyl)amino]-4-(3,5-difluorophenyl)-2-hydroxybutyl]amino}-3-(3-bromophenyl)propanoate;

N-[(1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{ [4-(3-ethylphenyl)tetrahydro-2*H*-pyran-4-yl]amino}-2-hydroxypropyl]-*N'*-phenylurea;

N-benzyl-*N'*-[(1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{ [(4*R*)-6-ethyl-2,2-dioxido-3,4-dihydro-1*H*-isothiochromen-4-yl]amino}-2-hydroxypropyl]urea;

N-[(1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{ [(4*R*)-6-ethyl-2,2-dioxido-3,4-dihydro-1*H*-isothiochromen-4-yl]amino}-2-hydroxypropyl]-*N'*-phenylurea;

N-[(1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{ [(4*R*)-6-ethyl-2,2-dioxido-3,4-dihydro-1*H*-isothiochromen-4-yl]amino}-2-hydroxypropyl]-*N'*-propylurea;

N-(*sec*-butyl)-*N'*-[(1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{ [(4*R*)-6-ethyl-2,2-dioxido-3,4-dihydro-1*H*-isothiochromen-4-yl]amino}-2-hydroxypropyl]urea;

N-{ (1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3,4-dihydro-2*H*-chromen-4-yl)amino]-2-hydroxypropyl}-*N'*-phenylurea;

N-{ (1*S*,2*R*)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-isopropyl-3,4-dihydro-2*H*-chromen-4-yl)amino]propyl}-*N'*-

phenylurea;

$N-[(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-3-(\{6-[(\text{dimethylamino})\text{methyl}]-3, 4\text{-dihydro-}2H\text{-chromen-}4\text{-yl}\}\text{amino})-2\text{-hydroxypropyl}]-N'\text{-phenylurea};$

$N-\{(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-3-[(6\text{-ethyl-}3, 4\text{-dihydro-}1H\text{-isochromen-}4\text{-yl})\text{amino}]-2\text{-hydroxypropyl}\}-N'\text{-phenylurea};$

$N-\{(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-2\text{-hydroxy-}3-[(6\text{-isopropyl-}3, 4\text{-dihydro-}1H\text{-isochromen-}4\text{-yl})\text{amino}]\text{propyl}\}-N'\text{-phenylurea};$


$N-[(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-3-(\{6-[(\text{dimethylamino})\text{methyl}]-3, 4\text{-dihydro-}1H\text{-isochromen-}4\text{-yl}\}\text{amino})-2\text{-hydroxypropyl}]-N'\text{-phenylurea};$

$N^3-[\{[(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-2\text{-hydroxy-}3-[(3\text{-methoxybenzyl})\text{amino}]\text{propyl}\}\text{amino})\text{carbonyl}]-N^1, N^1\text{-dipropyl-L-alaninamide};$ and


$2-\{[(\{[(1S, 2R)-1-(3, 5\text{-difluorobenzyl})-2\text{-hydroxy-}3-[(3\text{-methoxybenzyl})\text{amino}]\text{propyl}\}\text{amino})\text{carbonyl}]\text{amino}\}-N, N\text{-dipropylethanesulfonamide}.$

20. (Canceled)

21. (Previously presented) A compound which has the formula:



or



or a pharmaceutically acceptable salt thereof.

22. (Withdrawn-currently amended) A method of treating a patient who has, ~~or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, for treating cerebral amyloid angiopathy and preventing its potential consequences,~~

~~i.e. single and recurrent lobar hemorrhages, for
treating other degenerative dementias, including
dementias of mixed vascular and degenerative origin,
dementia associated with Parkinson's disease, dementia
associated with progressive supranuclear palsy,
dementia associated with cortical basal degeneration,
diffuse Lewy body type of Alzheimer's disease and who
is in need of such treatment which comprises
administration of a therapeutically effective amount
of a compound selected from the group consisting of a
substituted aminoalcohol of the formula (I), or a
pharmaceutically acceptable salt or ester thereof,
wherein X, T, R₂₀, R₁, R₂, R₃, R_N and R_C are as defined
in of claim 1 or a pharmaceutically acceptable salt or
ester thereof.~~

23. (Canceled)

24. (Previously presented) The compound according to claim 1 that is 3-(3-((2S,3R)-1-(3,5-difluorophenyl)-4-(1-(3-ethylphenyl)butylamino)-3-hydroxybutan-2-yl)ureido)-N,N-dipropylpropanamide.